Categories
Change Password!
Reset Password!
This 16-week randomized controlled trial explored the impact of a proactive treatment regimen using 2% crisaborole ointment on pediatric atopic dermatitis (AD).
In children with mild-to-moderate atopic dermatitis, proactive use of 2% crisaborole ointment decreases flare-ups and reliance on topical corticosteroids, with favorable safety and tolerability.
This 16-week randomized controlled trial explored the impact of a proactive treatment regimen using 2% crisaborole ointment on pediatric atopic dermatitis (AD).
In this study, pediatrics aged 2-17 years with mild-to-moderate AD were included. Participants were first treated with 0.1% mometasone furoate cream for 2 weeks. Those with an IGA score of ≤ 1 were then randomly assigned to either a proactive treatment group (crisaborole plus emollient twice daily) or a reactive group (emollient only). If a relapse occurred, both groups received 0.1% mometasone furoate cream as rescue therapy.
Of the 153 kids screened, 142 were randomly allocated (73 to proactive treatment group, 69 to reactive group). At the conclusion of the trial, the relapse rate in the proactive group was 43.84%, markedly lower than the 71.01% in the reactive group (P = 0.001). At weeks 4, 8, 12, and 16, proactive therapy led to fewer prescriptions for mometasone furoate (P < 0.05). Improvements were also witnessed in Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM) scores at 12 weeks (P < 0.05). No vital difference in adverse events was noted between the two groups (χ2 = 2.237, P = 0.135).
Proactively using crisaborole ointment in AD-affected children reduced flare-ups and dependence on topical corticosteroids, while proving to be well-tolerated and safe.
Pediatric Drugs
Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study
Huan Yang et al.
Comments (0)